
David S Leake

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3229840/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vitamins E and C do not effectively inhibit low density lipoprotein oxidation by ferritin at lysosomal pH. Free Radical Research, 2021, 55, 525-534.	3.3	3
2	Cysteamine Decreases Lowâ€Density Lipoprotein Oxidation, Causes Regression of Atherosclerosis, and Improves Liver and Muscle Function in Lowâ€Density Lipoprotein Receptor–Deficient Mice. Journal of the American Heart Association, 2021, 10, e017524.	3.7	11
3	Effect of vitamin E on low density lipoprotein oxidation at lysosomal pH. Free Radical Research, 2020, 54, 574-584.	3.3	4
4	Cysteamine inhibits lysosomal oxidation of low density lipoprotein in human macrophages and reduces atherosclerosis in mice. Atherosclerosis, 2019, 291, 9-18.	0.8	21
5	Lysosomal oxidation of LDL alters lysosomal pH, induces senescence, and increases secretion of pro-inflammatory cytokines in human macrophages. Journal of Lipid Research, 2019, 60, 98-110.	4.2	32
6	Antioxidants inhibit low density lipoprotein oxidation less at lysosomal pH: A possible explanation as to why the clinical trials of antioxidants might have failed. Chemistry and Physics of Lipids, 2018, 213, 13-24.	3.2	17
7	Low density lipoprotein oxidation by ferritin at lysosomal pH. Chemistry and Physics of Lipids, 2018, 217, 51-57.	3.2	8
8	The synthetic glycolipid-based TLR4 antagonist FP7 negatively regulates <i>in vitro</i> and <i>in vivo</i> haematopoietic and non-haematopoietic vascular TLR4 signalling. Innate Immunity, 2018, 24, 411-421.	2.4	11
9	Effect of low extracellular pH on NF-κB activation in macrophages. Atherosclerosis, 2014, 233, 537-544.	0.8	32
10	Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase–signaling pathways. Blood, 2013, 122, 580-589.	1.4	59
11	Oxidation of Low-Density Lipoprotein by Iron at Lysosomal pH: Implications for Atherosclerosis. Biochemistry, 2012, 51, 3767-3775.	2.5	30
12	Macrophage antioxidant protection within atherosclerotic plaques. Frontiers in Bioscience - Landmark, 2009, Volume, 1230.	3.0	30
13	Antioxidant activity and protective effects of green and dark coffee components against human low density lipoprotein oxidation. European Food Research and Technology, 2008, 227, 1017-1024.	3.3	35
14	A novel method for production of lipid hydroperoxide- or oxysterol-rich low-density lipoprotein. Atherosclerosis, 2008, 197, 579-587.	0.8	30
15	A moderate reduction in extracellular pH protects macrophages against apoptosis induced by oxidized low density lipoprotein. Journal of Lipid Research, 2008, 49, 782-789.	4.2	7
16	Low Density Lipoprotein Undergoes Oxidation Within Lysosomes in Cells. Circulation Research, 2007, 100, 1337-1343.	4.5	80
17	Mechanism of the antioxidant to pro-oxidant switch in the behavior of dehydroascorbate during LDL oxidation by copper(II) ions. Archives of Biochemistry and Biophysics, 2007, 465, 303-314.	3.0	16
18	Common variants of apolipoprotein A-IV differ in their ability to inhibit low density lipoprotein oxidation. Atherosclerosis, 2007, 192, 266-274.	0.8	47

#	Article	IF	CITATIONS
19	In Vitro Antioxidant Activity of Coffee Compounds and Their Metabolites. Journal of Agricultural and Food Chemistry, 2007, 55, 6962-6969.	5.2	192
20	Aqueous peroxyl radical exposure to THP-1 cells causes glutathione loss followed by protein oxidation and cell death without increased caspase-3 activity. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 945-953.	4.1	14
21	Ascorbate does not protect macrophages against apoptosis induced by oxidised low density lipoprotein. Archives of Biochemistry and Biophysics, 2006, 455, 68-76.	3.0	20
22	Effects of dairy products naturally enriched with cis-9,trans-11 conjugated linoleic acid on the blood lipid profile in healthy middle-aged men. American Journal of Clinical Nutrition, 2006, 83, 744-753.	4.7	148
23	Saturated fat-induced changes in Sf 60–400 particle composition reduces uptake of LDL by HepG2 cells. Journal of Lipid Research, 2006, 47, 393-403.	4.2	36
24	Induction of heme oxygenase 1 by moderately oxidized low-density lipoproteins in human vascular smooth muscle cells: Role of mitogen-activated protein kinases and Nrf2. Free Radical Biology and Medicine, 2005, 39, 227-236.	2.9	127
25	Role of Nrf2 in the Regulation of CD36 and Stress Protein Expression in Murine Macrophages. Circulation Research, 2004, 94, 609-616.	4.5	388
26	Degree of oxidation of low density lipoprotein affects expression of CD36 and PPARγ, but not cytokine production, by human monocyte-macrophages. Atherosclerosis, 2003, 168, 271-282.	0.8	25
27	Mechanisms by which cysteine can inhibit or promote the oxidation of low density lipoprotein by copper. Atherosclerosis, 2003, 169, 87-94.	0.8	29
28	Oxidation affects the flow-induced aggregation of low density lipoprotein and its inhibition by albumin. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1634, 24-29.	2.4	4
29	Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. Journal of Lipid Research, 2003, 44, 512-521.	4.2	124
30	Effects of oxidised low density lipoprotein on dendritic cells: a possible immunoregulatory component of the atherogenic micro-environment?. Cardiovascular Research, 2002, 55, 806-819.	3.8	96
31	Inhibition of lipoprotein-associated phospholipase A2diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Letters, 2001, 505, 357-363.	2.8	103
32	Flavonoids and the oxidation of low-density lipoprotein. Nutrition, 2001, 17, 63-66.	2.4	12
33	Measurement of Copper-Binding Sites on Low Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 594-602.	2.4	39
34	Vitamin C Protects Human Vascular Smooth Muscle Cells Against Apoptosis Induced by Moderately Oxidized LDL Containing High Levels of Lipid Hydroperoxides. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2387-2394.	2.4	105
35	Quantitative immunohistochemical detection of oxidized low density lipoprotein in the rabbit arterial wall. Experimental and Molecular Pathology, 1999, 65, 121-140.	2.1	4
36	Induction of antioxidant stress proteins in vascular endothelial and smooth muscle cells: Protective action of vitamin C against atherogenic lipoproteins. Free Radical Research, 1999, 31, 309-318.	3.3	25

#	Article	IF	CITATIONS
37	Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochemical Journal, 1999, 338, 479.	3.7	101
38	Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochemical Journal, 1999, 338, 479-487.	3.7	307
39	Human serum, cysteine and histidine inhibit the oxidation of low density lipoprotein less at acidic pH. FEBS Letters, 1998, 434, 317-321.	2.8	48
40	Vitamin C Protects Human Arterial Smooth Muscle Cells Against Atherogenic Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1662-1670.	2.4	53
41	Does an acidic pH explain why low density lipoprotein is oxidised in atherosclerotic lesions?. Atherosclerosis, 1997, 129, 149-157.	0.8	100
42	The effects of pH on the oxidation of low-density lipoprotein by copper and metmyoglobin are different. FEBS Letters, 1997, 406, 37-41.	2.8	23
43	Non-oxidative modification of low density lipoprotein by ruptured myocytes. FEBS Letters, 1997, 414, 576-580.	2.8	4
44	High-resolution mapping of the frequency of lipid deposits in thoracic aortae from cholesterol-fed and heritable hyperlipidaemic rabbits. Atherosclerosis, 1996, 120, 249-253.	0.8	15
45	Non-oxidative modification of native low-density lipoprotein by oxidized low-density lipoprotein. Biochemical Journal, 1996, 316, 377-380.	3.7	8
46	The effects of ascorbate and dehydroascorbate on the oxidation of low-density lipoprotein. Biochemical Journal, 1996, 320, 373-381.	3.7	33
47	Practical Approaches to Low Density Lipoprotein Oxidation: Whys, Wherefores and Pitfalls. Free Radical Research, 1996, 25, 285-311.	3.3	92
48	Induction of the antioxidant stress proteins heme oxygenase-1 and MSP23 by stress agents and oxidised LDL in cultured vascular smooth muscle cells. FEBS Letters, 1995, 368, 239-242.	2.8	75
49	Transition metal ions within human atherosclerotic lesions can catalyse the oxidation of low density lipoprotein by macrophages. FEBS Letters, 1995, 374, 12-16.	2.8	73
50	Oxidisability of low density lipoproteins in patients with carotid or femoral artery atherosclerosis. Atherosclerosis, 1995, 112, 77-84.	0.8	54
51	NADPH Oxidase Is Not Essential for Low-Density Lipoprotein Oxidation by Human Monocyte-Derived Macrophages. Biochemical and Biophysical Research Communications, 1994, 202, 1300-1307.	2.1	10
52	The effects of free radical scavengers on the oxidation of low-density lipoproteins by macrophages. Lipids and Lipid Metabolism, 1994, 1215, 250-258.	2.6	9
53	The effect of inhibitors of free radical generating-enzymes on low-density lipoprotein oxidation by macrophages. Lipids and Lipid Metabolism, 1994, 1211, 69-78.	2.6	48
54	Iron released from transferrin at acidic pH can catalyse the oxidation of low density lipoprotein. FEBS Letters, 1994, 352, 15-18.	2.8	56

#	Article	IF	CITATIONS
55	Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein. FEBS Letters, 1994, 338, 122-126.	2.8	87
56	The oxidation of low density lipoprotein by cells or iron is inhibited by zinc. FEBS Letters, 1994, 341, 259-262.	2.8	45
57	Ascorbic acid can either increase or decrease low density lipoprotein modification. FEBS Letters, 1994, 341, 263-267.	2.8	40
58	Acidic pH increases the oxidation of LDL by macrophages. FEBS Letters, 1993, 333, 275-279.	2.8	26
59	The modification of low density lipoprotein by the flavonoids myricetin and gossypetin. Biochemical Pharmacology, 1993, 45, 67-75.	4.4	55
60	Oxidation of low density lipoprotein by bovine and porcine aortic endothelial cells and porcine endocardial cells in culture. Atherosclerosis, 1993, 102, 209-216.	0.8	22
61	CD4-positive T-lymphocytes can oxidatively modify low density lipoprotein. Biochemical Society Transactions, 1993, 21, 132S-132S.	3.4	1
62	The effect of EDTA on the oxidation of low density lipoprotein. Atherosclerosis, 1992, 94, 35-42.	0.8	44
63	The oxidative modification of low density lipoprotein by human lymphocytes. Atherosclerosis, 1992, 92, 187-192.	0.8	63
64	The interaction between ruptured erythrocytes and low‐density lipoproteins. FEBS Letters, 1992, 303, 154-158.	2.8	64
65	Free radicals and low-density lipoprotein oxidation by macrophages. Biochemical Society Transactions, 1990, 18, 1170-1171.	3.4	17
66	Modification of low-density lipoproteins by flavonoids. Biochemical Society Transactions, 1990, 18, 1172-1173.	3.4	11
67	Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochemical Pharmacology, 1990, 39, 1743-1750.	4.4	566
68	Macrophage proteases can modify low density lipoproteins to increase their uptake by macrophages. FEBS Letters, 1990, 269, 209-212.	2.8	13
69	The effects of acetylated low-density lipoproteins on fluid-phase pinocytosis by macrophages. FEBS Journal, 1989, 182, 407-412.	0.2	2
70	Macrophages possess both neutral and acidic protease activities toward low density lipoproteins. Atherosclerosis, 1989, 79, 71-78.	0.8	21
71	The effect of macrophage stimulation on the uptake of acetylated low-density lipoproteins. Lipids and Lipid Metabolism, 1989, 1005, 196-200.	2.6	21
72	Lysosomal engorgement inhibits fluid-phase pinocytosis in macrophages. Biochemical Society Transactions, 1987, 15, 432-433.	3.4	1

#	Article	IF	CITATIONS
73	The modification of low-density lipoproteins by macrophages in relation to atherosclerosis. Biochemical Society Transactions, 1987, 15, 485-486.	3.4	18
74	Receptor-mediated endocytosis or pinocytosis?. Trends in Biochemical Sciences, 1986, 11, 509.	7.5	0
75	Macrophages contain neutral protease activity toward low-density lipoproteins. Biochemical Society Transactions, 1986, 14, 1084-1085.	3.4	1
76	Subcellular fractionation of arterial smooth muscle cells laden with lipid following incubation with low density lipoproteins and chloroquine. Experimental and Molecular Pathology, 1983, 38, 82-99.	2.1	5
77	Properties and subcellular localization of elastase-like activities of arterial smooth muscle cells in culture. Biochimica Et Biophysica Acta - General Subjects, 1983, 761, 41-47.	2.4	42
78	Properties and subcellular localization of adenosine diphosphatase in arterial smooth muscle cells in culture. Biochimica Et Biophysica Acta - Molecular Cell Research, 1983, 762, 52-57.	4.1	27
79	A large proportion of the acid phosphatase activity in arterial smooth-muscle cells is associated with the plasma membrane. Biochemical Society Transactions, 1982, 10, 35-36.	3.4	4
80	Lipid accumulation in arterial smooth muscle cells in culture Morphological and biochemical changes caused by low density lipoproteins and chloroquine. Atherosclerosis, 1982, 44, 275-291.	0.8	21
81	Modification of the rate of pinocytosis in arterial smooth muscle cells in culture. Experimental and Molecular Pathology, 1982, 36, 262-275.	2.1	4
82	Properties and Subcellular Localization of Acid Phosphatase Activity in Cultured Arterial Smooth Muscle Cells. FEBS Journal, 1982, 128, 557-563.	0.2	11
83	Subcellular Localization of Adenosine Diphosphatase in Cultured Pig Arterial Endothelial Cells. Thrombosis and Haemostasis, 1982, 47, 249-253.	3.4	25
84	Proteolytic degradation of low density lipoproteins by arterial smooth muscle cells. Lipids and Lipid Metabolism, 1981, 664, 108-116.	2.6	26
85	Quantitative studies of pinocytosis by arterial endothellal and smooth muscle cells in culture. Experimental and Molecular Pathology, 1981, 35, 84-97.	2.1	19
86	Quantitative Studies of Pinocytic Uptake of 125I-Labelled Polyvinylpyrrolidone by Pig Aortic Smooth-Muscle Cells in Culture. Biochemical Society Transactions, 1977, 5, 130-133.	3.4	7